OTUD7B upregulation predicts a poor response to paclitaxel in patients with triple-negative breast cancer

Paclitaxel is a first-line chemotherapeutic for patients with breast cancer, particularly triple-negative breast cancer (TNBC). Molecular markers for predicting pathologic responses to paclitaxel treatment is thus urgently needed since paclitaxel resistance is still a clinical issue in treating TNBC...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiu, Hui-Wen, Lin, Hui-Yu, Tseng, Ing-Jy, Lin, Yuan-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787489/
https://www.ncbi.nlm.nih.gov/pubmed/29416635
http://dx.doi.org/10.18632/oncotarget.23074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787489/
https://www.ncbi.nlm.nih.gov/pubmed/29416635
http://dx.doi.org/10.18632/oncotarget.23074

Ejemplares similares